Public Funding for Uniq Health Ltd

On the 12th October the UK GOV the all-party parliamentary group on menopause (APPG) said that more needs to be done urgently to help women, including earlier screening , introducing fresh training on symptoms for health workers, and improving access to treatment. "Millions of women across the UK should be invited for an NHS health check at the age of 45 to discuss the menopause and HRT prescriptions should be free, MPs have said. "We are beginning to feel the tide of change but the taboo around the menopause still prevails in all corners of society -- in workplaces, within families and among friends, in education, and in the medical profession," said Labour MP Carolyn Harris, the chair of the APPG. "Access to HRT remains a postcode lottery for women in the UK and there is a stark divide between those who can afford to seek treatment elsewhere, and those who cannot. Half the population will experience the menopause, but an "entrenched taboo" around women's health issues means support for the 13 million women going through perimenopause or the menopause is "completely inadequate", MPs warn. "The NHS must implement a health check for all women at the age of 45, offered in a similar way to cervical cancer smears when all women are invited to make an appointment," its report will say. "This is crucial to ensure women are engaged with the health system ahead of or in the early stages of perimenopause, help diagnose menopause at an earlier stage and ensure women are better prepared, and have the right information and treatment they need to manage the menopause transition." - APPG report 12th October 2022\. Tuune are a Google-backed female hormonal health company focussed on improving current care pathways, for both doctors and patients, for the menopause and other hormonal health conditions through the use of data, AI and technology. Addressing the challenges outlined by the APPG, we are a building new AI-based menopausal and perimenopausal pre-screening and support tool for GPs and Patients, to address the diagnosis and care challenges associated with 1.3m perimenopausal women, aged 35-45, in the UK, improve care and address the inefficiencies in the current system.

Covid 19 has validated and compounded the need for improved efficiencies (identified within the NHS Long Term plan) via the urgent introduction of automation and the utilisation of Telemedicine where feasible to reduce strain on resources, especially with the prospect of a second wave/future spikes on the horizon. The ongoing impact of Covid-19 meant over 45% of non-urgent appointments were either cancelled or postponed, leaving GP's with significant backlogs. Contraception and prescription of Oral Contraceptives (OC) is the second most common reason to visit a GP (UK), accounting for more than 20m appointments/annum, equivalent to 13,900 days and is classed as "non-urgent." This has been further compounded by the closure of 54% of Sexual Health Clinics, often utilised by young females for contraceptive consultations, leaving many unsupported. Intelligent, automated technology, as identified in the NHS Long-Term/NIHR post-Covid strategies, can help in this regard in particular when combined with recently curated large female health datasets on hormonal profiles. Reducing demand on GP clinics whilst improving the prescribing process by ensuring optimum available medication is prescribed first time (52% of users suffer side-effects on the first prescribed medication, on average resulting in 2 further consultations to manage adverse side-effects and determine optimum medication). Building upon our CE-Marked hormonal health platform and prototype TRL5 patient stratification algorithms, we intend to develop and trail (alongside NHS partner CNWL NHS Trust) a new Telemedicine platform for female contraceptive treatments that will; * Automate the consultation and triage process * Intelligently/accurately select the optimum available OC via patient stratification (utilising advanced algorithms) that considers a woman's unique hormone profile * Ongoing remote outreach and monitoring by our digital support hub-\> earlier detection of side-effects, mitigation through counselling/coaching /medication changes where warranted. **Impact** The project addresses both a long-term inefficiency in the current prescribing method, as well as addresses the immediate impact of COVID-19 on GPs/Primary Care. The technology will explicitly; 1. Remove the need for a GP in 70% of all cases via remote triage: saving ~9730 GP-days/annum. 2. Improve the triage process for remaining 30% of complex cases via our CE-Marked knowledge base for GPs. 3. Improve the accuracy of medication prescription through AI-assisted patient stratification, reducing re-consultations by ~60%. 4. Enable remote prescribing via our partners Pharmacy2U&Mayberry\_Pharmacy 5. Help reduce the ~£1.9Bn cost to the NHS of hormonal medication related side-effects(NHS:2019) 6. Improve patient care and proactive management through digital outreach and interaction. 7. Can be rolled out nationally, at scale, quickly.